Investigational drug · Phase 2
KL1333
Also called: Napazimone
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Mitochondrial Disease, Mitochondrial Diseases.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "KL1333"
First trial start
2022
Dec 13, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KL1333", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Mitochondrial Disease
- Mitochondrial Diseases
Largest trials
Live from ClinicalTrials.gov: studies naming "KL1333" as an intervention, largest first.
- Efficacy of KL1333 in Adult Patients With Primary Mitochondrial DiseasePivotal-lookingRecruiting
Pharming Technologies B.V.Industry
NCT05650229 · 180 participants (planned) · Start Dec 13, 2022 · Primary completion Oct 2027
Drug: KL1333; Placebo · For: Primary Mitochondrial Disease
Sites: Orange, California; San Diego, California; San Francisco, California · 55 sites in all
Pharming Technologies B.V.Industry
NCT07514338 · 140 participants (planned) · Start Jun 12, 2026 · Primary completion Mar 31, 2029
Drug: Napazimone · For: Mitochondrial Diseases
Sites: Akron, Ohio; Brussels, Belgium; Ghent, Belgium · 23 sites in all
Abliva ABIndustry
NCT03888716 · 72 participants · Start Mar 18, 2019 · Primary completion Mar 16, 2021
Drug: KL1333; Placebo Oral Tablet · For: Mitochondrial Diseases; Mitochondrial Respiratory Chain Deficiencies; MELAS Syndrome and 1 more
Sites: Leeds, United Kingdom; London, United Kingdom
Yungjin Pharm. Co., Ltd.Industry
NCT03056209 · 60 participants · Start Jun 26, 2017 · Primary completion Apr 16, 2018
Drug: KL1333 25 mg; KL1333 50 mg and 6 more · For: MELAS Syndrome; Mitochondrial Respiratory Chain Deficiencies
Sites: Seoul, South Korea
Abliva ABIndustry
NCT04643249 · 14 participants · Start Nov 10, 2020 · Primary completion Dec 17, 2020
Drug: KL1333; Flurbiprofen and 6 more · For: Mitochondrial Disease
Sites: Leeds, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Mitochondrial DNA A3243G variant-associated MELAS: Recent advances in clinical trials, therapeutic interventions, and disease-modifying strategies.
Chu KY · Intractable Rare Dis Res 2026
- Optimizing rare disorder trials: a phase 1a/1b randomized study of KL1333 in adults with mitochondrial disease.
Pizzamiglio C, Stefanetti RJ, McFarland R, et al. · Brain 2025
- KL1333, a derivative of β-lapachone, protects against cisplatin-induced ototoxicity in mouse cochlear cultures.
Lee HS, Kim YR, Lee IK, et al. · Biomed Pharmacother 2020
- KL1333, a Novel NAD+ Modulator, Improves Energy Metabolism and Mitochondrial Dysfunction in MELAS Fibroblasts.
Seo KS, Kim JH, Min KN, et al. · Front Neurol 2018
Also in development for Primary Mitochondrial Disease
- OMT-28Phase 21 trial
Omeicos Therapeutics GmbH · Primary Mitochondrial Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.